ACETIC-1-13C ACID
Clear Cell Carcinoma
University of Texas Southwestern Medical CenterSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
13 Active assets in the Clear Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Dana-Farber Cancer Institute | Phase 2 | B |
Rucaparib North Eastern German Society of Gynaecological Oncology | Phase 3 | B |
Lorigerlimab MacroGenics | Phase 2 | CCC |
Dostarlimab Yonsei University | Phase 2 | CCC |
Inno-206 Yonsei University | Phase 2 | CCC |
View all 20 →
Same molecule, other indications
ACETIC-1-13C ACID is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →